HIGHLIGHTS
- who: Yuxiang Ma from the (UNIVERSITY) have published the paper: Phase I study of camrelizumab in patients with advanced solid tumors, in the Journal: (JOURNAL) of 28/09/2022
- what: The study evaluated the impact of continuous peripheral blood RO on the efficacy of camrelizumab although it may not fully
- future: Studies including exposure-response studies are needed to better inform clinical dosing strategies.
SUMMARY
Received reflect the intra-tumor and differentiated non-activated T_cells in RO, it still provides a better understanding of the therapeutic efficacy of camrelizumab . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.